Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.62 - $2.04 $1.9 Million - $2.39 Million
1,170,060 Added 390.42%
1,469,754 $2.59 Million
Q1 2024

May 15, 2024

BUY
$1.66 - $2.42 $497,492 - $725,259
299,694 New
299,694 $566,000
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $1.46 Million - $2.36 Million
-815,280 Reduced 21.08%
3,051,569 $7.51 Million
Q1 2023

May 15, 2023

SELL
$2.65 - $3.81 $673,105 - $967,747
-254,002 Reduced 6.16%
3,866,849 $11.5 Million
Q4 2022

Feb 14, 2023

BUY
$3.38 - $4.22 $8.21 Million - $10.3 Million
2,429,531 Added 143.65%
4,120,851 $15 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $740,958 - $1.26 Million
216,023 Added 14.64%
1,691,320 $6.09 Million
Q2 2022

Aug 15, 2022

SELL
$4.41 - $5.69 $993,445 - $1.28 Million
-225,271 Reduced 13.25%
1,475,297 $7.8 Million
Q1 2022

May 16, 2022

SELL
$4.81 - $6.99 $2.09 Million - $3.03 Million
-433,712 Reduced 20.32%
1,700,568 $9.34 Million
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $18,393 - $24,432
-3,081 Reduced 0.14%
2,134,280 $14.5 Million
Q3 2021

Nov 15, 2021

SELL
$4.79 - $6.68 $410,306 - $572,202
-85,659 Reduced 3.85%
2,137,361 $13 Million
Q2 2021

Aug 13, 2021

SELL
$5.35 - $6.35 $1.78 Million - $2.12 Million
-333,128 Reduced 13.03%
2,223,020 $13.1 Million
Q1 2021

May 17, 2021

BUY
$5.68 - $7.87 $1.83 Million - $2.53 Million
321,868 Added 14.41%
2,556,148 $15.4 Million
Q4 2020

Feb 16, 2021

BUY
$5.25 - $8.56 $234,438 - $382,246
44,655 Added 2.04%
2,234,280 $15.5 Million
Q3 2020

Nov 16, 2020

BUY
$5.78 - $7.47 $1.2 Million - $1.54 Million
206,785 Added 10.43%
2,189,625 $13.7 Million
Q2 2020

Aug 14, 2020

BUY
$4.5 - $7.02 $8.92 Million - $13.9 Million
1,982,840 New
1,982,840 $13.1 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $331M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Hood River Capital Management LLC Portfolio

Follow Hood River Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hood River Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hood River Capital Management LLC with notifications on news.